Skip to content

The potential of psychedelic medicine - A personal account.

David E Smith

Journal of the Neurological Sciences March 15, 2022 DOI: 10.1016/j.jns.2021.120128 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Historical analysis Peer reviewed
Topics Addiction LSD
Keywords Entactogens Entheogens Psychedelics Recovery Therapeutic drugs Early use Therapeutic applications Historical account Haight ashbury Halted research Negative publicity Schedule 1 classification Suppressing exploration Sidelined Untapped potential Studied compounds
Key points Argues that the criminalization and Schedule 1 classification of psychedelics, beginning in 1966, shut down research almost entirely.

Abstract

In 1965, I was training in clinical toxicology in the pharmacology department of the University of California San Francisco (UCSF) and living in the Haight Ashbury. I studied various psychedelics, including LSD, mescaline, and ibogaine, in human and animal models. The psychedelics were then being used as a therapeutic drug in clinical settings and researched as a potential antipersonnel agent by the U.S. government. Then, using psychedelics became a rite of passage for the emerging countercultural movement. After adverse reactions and negative publicity, states began to criminalize these drugs, beginning in 1966. The federal government eventually moved these drugs to Schedule 1 classification, shutting down research almost entirely.

Comparable studies

Other theoretical and historical papers on LSD for addiction, most cited first.

Explore topics

By condition and practice